U.S. markets open in 2 hours 24 minutes

  • S&P Futures

    3,884.00
    +19.50 (+0.50%)
     

  • Dow Futures

    31,101.00
    +151.00 (+0.49%)
     

  • Nasdaq Futures

    13,595.25
    +47.75 (+0.35%)
     

  • Russell 2000 Futures

    2,218.60
    +19.20 (+0.87%)
     

  • Crude Oil

    56.76
    +0.53 (+0.94%)
     

  • Gold

    1,803.80
    +12.60 (+0.70%)
     

  • Silver

    26.64
    +0.41 (+1.55%)
     

  • EUR/USD

    1.1983
    +0.0017 (+0.14%)
     

  • 10-Yr Bond

    1.1390
    0.0000 (0.00%)
     

  • Vix

    21.76
    -1.15 (-5.02%)
     

  • GBP/USD

    1.3689
    +0.0020 (+0.15%)
     

  • USD/JPY

    105.6040
    +0.0790 (+0.07%)
     

  • BTC-USD

    37,558.27
    +52.01 (+0.14%)
     

  • CMC Crypto 200

    775.25
    +9.58 (+1.25%)
     

  • FTSE 100

    6,509.65
    +5.93 (+0.09%)
     

  • Nikkei 225

    28,779.19
    +437.24 (+1.54%)
     
COMING UP:

U.S. employers likely added 100,000 jobs in January; jobless rate likely same at 6.7%

Check back at 8:30 a.m. ET for the results

Fuel-Cell Truck Startup Hyzon Agrees to Merge With Decarbonization Plus SPAC

Ed Ludlow and Gillian Tan
·2 min read

(Bloomberg) -- Hyzon Motors Inc., a fuel cell truck startup, has agreed to go public via a merger with Decarbonization Plus Acquisition Corp., according to people with knowledge of the matter.

The special purpose acquisition company has held discussions about raising new equity to support the transaction that values the combined entity at more than $2 billion, some of the people said, requesting anonymity because the talks are private. A deal could be announced within the next week.

Representatives for Hyzon and Decarbonization Plus declined to comment. Shares of the SPAC surged 28% as of 5 a.m. Friday in New York, before the start of regular trading.

Decarbonization Plus, a vehicle sponsored by an affiliate of private equity firm Riverstone Holdings and led by Erik Anderson, raised about $226 million in an October initial public offering. It said at the time it wanted to find a target “whose principal effort is developing and advancing a platform that decarbonizes the most carbon-intensive sectors.”

Hyzon was spun out of Singapore-based Horizon Fuel Cell Technologies Pte, which has been developing fuel cell technology for commercial applications for almost 20 years. The startup, which counts Total SE among its investors, makes hydrogen-powered big rigs, buses and coaches.

Hyzon is headquartered at a former General Motors Co. facility in Honeoye Falls, New York. In July, it announced plans for a plant in the Netherlands as part of a joint venture with Holthausen Clean Technology BV. It also has unspecified manufacturing activities with an undisclosed partner in Shanghai, and operations in Australasia.

Hyzon says it already has more than 400 commercial vehicles on the road using its fuel cell technology. It expects to deliver about 5,000 fuel cell-powered trucks and buses by 2023 and is targeting annual capacity of around 40,000 fuel cell-electric vehicles by 2025. In August, Hyzon inked a deal with Australian mining company Fortescue Metals Group Ltd. to build a fleet of hydrogen fuel cell buses.

EV companies including Nikola Corp., Fisker Inc. and Arrival Ltd. have agreed to go public through SPAC mergers.

(Updates with shares trading in the third paragraph.)

For more articles like this, please visit us at bloomberg.com

Subscribe now to stay ahead with the most trusted business news source.

©2021 Bloomberg L.P.

Latest Stories

  • Sundial Growers Closes $74.5M Offering After Being Targeted By WallStreetBets

    Sundial Growers Inc. (NASDAQ: SNDL) closed a share offering valued at roughly $74.5 million this week. The Calgary, Canada-based company currently has some $610 million in cash, in addition to marketable securities and loans receivable of approximately $61 million, and approximately 1.56 billion common shares outstanding. Deal Breakdown Sundial unveiled a registered offering of 60.5 million Series A Units sold at a price of about $1 each. Some 14 million Series B Units were sold at a price of $1 each, minus $0.0001. The remaining exercise price of each Series B Warrant is equal to US$0.0001 per common share, according to a release. The exercise price of the company's Series A Warrants is equal to $1.10 per common share. A warrant gives the stock holder the right to buy a company's stock at a specific price and at a specific date. Sundial's Week Sundial shares closed nearly 48.5% higher on Monday, dipped Tuesday, but spiked 16% on Wednesday. By Thursday, the company's shares opened at $1.25 each. By 3:20 p.m. EST, they hovered $1.17 per share. The company was once dubbed a "unicorn" due to its valuation, which at one point hovered at $1 billion. These days, Sundial is among a list of so-called “meme stocks” in the crosshairs of Reddit investor group r/WallStreetBets investors, as compiled by Swaggy Stocks. The r/WallStreetBets group has over 8 million members and recently grabbed headlines for buying shares of companies such as GameStop Corp. (NYSE: GME) and AMC Entertainment Holdings Inc. (NYSE: AMC), which are similarly heavily shorted. See more from BenzingaClick here for options trades from BenzingaCbdMD To Donate Up To 0K From Sales To Portnoy's Barstool FundPetalfast CEO: THC-Infused Aperitif Is A No-Brainer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • These Stocks Could Soar As The U.S.-China Electric Vehicle War Heats Up

    China is attempting to dominate the projected $802 billion electric vehicle market, but America could pull ahead with the help of innovative companies.

  • Four High Dividend Stocks You Can Count On

    High-dividend stocks can be misleading. Here's a smart way to find stable stocks with high dividends. Watch these five dividend payers on IBD's radar.

  • Your next stimulus check: Congress is speeding $1,400 payments along

    Speaker Pelosi and other leaders want quick approval. How soon could you get more money?

  • Regeneron's stock rallies after profit rises well above expectations, while revenue matches

    Shares of Regeneron Pharmaceuticals Inc. jumped 3.0% in premarket trading Friday, after the biotechnology company reported a fourth-quarter profit that rose well above expectations, while revenue was in line with forecasts. Net income increased to $1.15 billion, or $10.24 a share, from $792.0 million, or $6.93 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share grew to $9.53 from $7.50, to beat the FactSet consensus of $8.38. Revenue increased 30% to $2.42 billion, matching the FactSet consensus. Regeneron's REGEN-COV antibody cocktail for COVID-19 received Emergency Use Authorization from the FDA in November. In January, the company announced a second agreement with the U.S. government to deliver 1.25 million additional doses of REGEN-GOV. "In 2021, in addition to our ongoing work on COVID-19, we expect further diversified growth driven by continued EYLEA momentum, expanded approvals and increased market penetration for Dupixent, and new launches for Libtayo in oncology," said Chief Executive Leonard Schleifer. The stock has dropped 15.3% over the past three months through Thursday, while the S&P 500 has gained 10.3%.

  • The Average 401(k) Balance by Age

    Are you putting away enough for retirement? See how your 401(k) savings stacks up against your peers.

  • Electric Aircraft Startup Archer to Go Public at Multibillion Dollar Valuation via SPAC – Sources

    By John Jannarone and Jarrett Banks Electric aircraft startup Archer Aviation Inc. plans to go public by merging with a special purpose acquisition company, or SPAC, in a deal that will give the company a multibillion dollar valuation, according to people familiar with the matter. The announcement could come as early as next week, these people told IPO […]

  • There Are Still 16 Meme Stocks With at Least 100% Gains in 2021

    (Bloomberg) -- While it may seem that the “meme stock” mania is dissipating following GameStop Corp.’s $27 billion wipe-out, there are still 16 companies whose shares are up triple digits this year.Of the 50 stocks that Robinhood originally put on its restricted list, roughly a third have doubled or more in price in 2021, while only six are lower year-to-date. Leading the pack is Naked Brand Group Ltd., whose shares are 546% higher this year. Koss Corp. is up 528% while GameStop shares are still hanging onto a gain of 317%.It’s a reminder that the wild ride may be far from over for these stocks. While $164 billion in value has been wiped from those 50 companies in a matter of days, data compiled by Bloomberg show, that came after $276 billion in market cap was added from the start of the year through the height of the frenzy.“There’s still a huge appetite for this type of trading,” said Chris O’Keefe, managing director at Logan Capital Management. “There’s still a lot of energy to continue to speculate on the stock market.”Over the past 24 hours, AMC Entertainment Holdings Inc., Churchill Capital Corp., GameStop and Sundial Growers Inc. were the four most-frequently mentioned stocks on Stocktwits -- which bills itself as the largest community for investors and traders -- according to data compiled by Bloomberg. All four were among the 50 stocks curbed by Robinhood last week, and all four are up at least 150% in 2021.It’s likely that any unwind is going to take weeks, rather than days, due to the fact that professional investors have gotten involved too, according to Arthur Hogan, chief market strategist at National Securities Corp. For example, hedge fund Mudrick Capital Management gained almost $200 million from its stakes in stocks including AMC and GameStop.“This trend, or the unwind of the crazy short squeeze, likely is going to take a little bit longer than a couple of days,” Hogan said. “The fundamental driver behind that taking longer has to do with the players -- it’s not all a bunch of guys sitting in their mom’s basement.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • The 5G Revolution Could Send These 3 Stocks Higher

    We’ve got a full month of 2021 behind us now, and a few trends are coming clearer. The coronavirus crisis may still be with us, but as vaccination programs expand, the end is in sight. With President Trump out of the picture, and the Democrats holding both Houses of Congress and the White House, politics is looking more predictable. And both of those developments bode well for an economic recovery this year. Looking back, at the year that was, we can also see some trends that stayed firm despite the pandemic, the shutdowns, and the supercharged election season. One of the most important is the ongoing rollout of 5G networking technology. These new networks bring with them a fuller realization of the promises inherent in the digital world. Faster connections, lower latency, higher online capacity, clearer signals – all will strongly enhance the capabilities of the networked world. And it won’t just be mundane things like telecommuting or remote offices that will benefit – 5G will allow Internet of Things and autonomous vehicles to further develop their potential. There is even talk of medical applications, of remotely located doctors performing surgery via digitally controlled microsurgical tools. And these are just the possibilities that we can see from now. Who know what the future will really bring? To this end, we pulled up TipRanks’ database to learn more about three exciting plays in the 5G space. According to the Street, we are likely to see further interesting developments in the next few years as this technology takes over. Skyworks Solutions (SWKS) The first 5G name we’re looking at, Skyworks, is a semiconductor chip manufacturer that brought in $3.4 billion in total revenues for FY2020. Skyworks, which is a prime supplier of chips for Apple’s iPhone series, saw a massive 68% year-over-year increase in 1QFY21 revenues – the top line reached $1.51 billion, a company record, and also much higher than analysts had forecast. Much of Skyworks’ fiscal Q1 sales success came after Apple launched the 5G-capable iPhone 12 line. Strong sales in the popular handset device meant that profits trickled down the supply line – and Skyworks channels a disproportionate share of its business to Apple. In fact, Apple orders accounted for 70% of Skyworks’ revenue in the recent quarter. iPhone wasn’t the only 5G handset on the receiving end of Skyworks’ chips, however – the company is also an important supplier to Korea’s Samsung and China’s Xiaomi, and has seen demand rise as these companies also launch 5G-capable smartphones. Finally, Skyworks supplies semiconductor chip components to the wireless infrastructure sector, specifically to the ‘small cell’ transmission units which are important in the propagation network of wireless signals. As the wireless providers switch to 5G transmission, Skyworks has seen orders for its products increase. In his note on Skyworks for Benchmark, 5-star analyst Ruben Roy writes: “SWKS significantly beat consensus estimates and provided March quarter guidance that is also well ahead of consensus estimates as 5G related mobile revenue and broad-based segment revenue continued to accelerate… In addition to continued strength of design win momentum and customer activity, we are encouraged with SWKS confident tone relative to the overall demand environment and content increase opportunities.” In line with his comments, Roy rates SWKS a Buy along with a $215 price target. At current levels, this implies an upside of 20% for the coming year. (To watch Roy’s track record, click here) Roy is broadly in line with the rest of Wall Street, which has assigned SWKS 13 Buy ratings and 7 Holds over the past three month -- and sees the stock growing about 15% over the next 12 months, to a target price of $205.69.(See SWKS stock analysis on TipRanks) Qorvo, Inc. (QRVO) Qorvo’s chief products are chipsets used in the construction of radio frequency transmission systems that power wifi and broadband communication networks. The connection of this niche to 5G is clear – as network providers upgrade their RF hardware to 5G, they also upgrade the semiconductor chips that control the systems. This chip maker has a solid niche, but it is not resting on its laurels. Qorvo is actively developing a range of new products specifically for 5G systems and deployment. This 5G radio frequency product portfolio includes phase shifters, switches, and integrated modules, and contains both infrastructure and mobile products. Qorvo posted $3.24 billion in total revenues for fiscal 2020. That revenue represents a 4.8% year-over-year increase – and the company’s sales have been accelerating in fiscal 2021. The most recent quarterly report, for the second fiscal quarter, showed $1.06 billion in revenues, a 31% yoy increase. Rajvindra Gill, 5-star analyst with Needham, is bullish on Qorvo’s prospects, noting: “Qorvo reported strong sales and gross margins as 5G momentum rolls into CY21 on atypical seasonality... The company is planning for 500M 5G handsets to be manufactured in 2021, with an incremental $5-7 of content/unit from 4G to 5G. Management believes that ultra-wideband adoption will be a key growth driver in for smartphones going forward..." To this end, Gill puts a $220 price target on QRVO shares, suggesting room for 31% upside in 2021. Accordingly, he rates the stock a Buy. (To watch Gill’s track record, click here) What do other analysts have to say? 13 Buys and and 6 Holds add up to a Moderate Buy analyst consensus. Given the $192.28 average price target, shares could climb ~15% from current levels. (See QRVO stock analysis on TipRanks) Telefonakiebolaget LM Ericsson (ERIC) From chipsets, we’ll move on to handsets. Ericsson, the Swedish telecom giant has long been a leader in mobile tech, and is well known for its infrastructure and software that make possible IP networking, broadband, cable TV, and other telecom services. Ericsson is the largest European telecom company, and the largest 2G/3G/4G infrastructure provider outside of China. But that is all in the background. Ericsson is also a leader in the rollout of Europe’s growing 5G networks. Ericsson is involved in 5G rollout in 17 countries in Europe, the Americas, and Asia, and its product line includes infrastructure base units and handsets, giving the company an interest in all aspects of the new 5G networks. Ericsson’s revenue performance in 2020 was not notably distressed by the corona crisis. Yes, the top line dipped in Q1, but that was in line with the company’s historical pattern of rising revenue from Q1 through Q4. While the company’s 1H20 revenues showed small yoy declines, the 2H20 gains were higher. In Q3, the $6.48 billion top line was up 8.7% yoy, and Q4’s $8.08 billion revenue was up 17% from the prior year. The company’s shares have also performed well during the ‘corona year,’ and show a 12 month gain of 64%. Raymond James’ 5-star analyst Simon Leopold bluntly assigns Ericsson’s recent gains to its participation in 5G rollouts. “Japan's awaited 5G roll-out has started. Share gains continue as Ericsson benefits from challenges facing its biggest competitors and more operators embrace 5G… it seems obvious that Ericsson should be gaining market share... Competitor Nokia shunned the Chinese 5G projects, citing profitability challenges, yet Ericsson appears to be profiting in the challenging region.” Leopold rates this stock an Outperform (i.e. Buy), and his $15 price target implies an upside potential of ~14% for the year ahead. (To watch Leopold’s track record, click here) The Raymond James analyst, while bullish on ERIC, is actually less so than the Wall Street consensus. The stock has a Strong Buy consensus rating, based on a unanimous 5 reviews, and the $16.50 average price target indicates 25% growth potential from the share price of $13.19. (See ERIC stock analysis on TipRanks) To find good ideas for 5G stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Dow Jones Futures: Hot Stock Market Rally Flashes Warning; GameStop Tries To Bounce As Pinterest, Peloton, Snap Lead Earnings Movers

    Futures rose modestly. The stock market rally is at highs, but extended again. GameStop is trying to bounce early. Pinterest and Snap lead big earnings movers.

  • China's Luckin Coffee seeks U.S. Chapter 15 bankruptcy protection

    The coffee chain said the Chapter 15 petition, which would facilitate the restructuring of its debts, is not expected to materially impact its day-to-day operations, and that its stores remain open. Chapter 15 bankruptcy allows a foreign debtor to shield assets in the United States. Xiamen-based Luckin had positioned itself as an ambitious home-grown challenger to U.S. coffee giant Starbucks Corp , but said last April that as much as 2.2 billion yuan ($340 million) in 2019 sales had been fabricated.

  • Investors Have Shunned Utilities Despite Their Steady Dividends. Here Are 6 to Consider for Yield.

    Many utility stocks have remained unloved through much of the pandemic, their attractive yields and reliable dividends notwithstanding.

  • 2 “Strong Buy” Penny Stocks With Over 200% Upside on the Horizon

    Let’s talk about risk and the big picture. It’s an appropriate time, as the big risk – presented by the COVID-19 pandemic – is finally receding thanks to the ongoing vaccination program. COVID is leaving behind an economy that was forced into shutdown one year ago while in the midst of a great expansion, boosted by the deregulation policies. While the new Biden Administration is busy reversing many Trump policies, at least for now the economy is rebounding. And this brings us to risk. A time of economic growth and rebound is a forgiving time to move toward risk investments, as general economic growth tends to lift everything. Two strategists from JPMorgan have recently chimed in, promoting the view that the market’s fundamentals are still sound, and that small- to mid-cap sector is going to keep rising. First, on the general conditions, quant strategist Dubravko Lakos-Bujas wrote, “Although the recent technical selloff and short squeeze is receiving a lot of attention, we believe the positive macro setup, improving fundamentals and COVID-19 outlook, strength of the US consumer, as well as the reflation theme remain the bigger forces at play. Not only should this drive further equity upside, but it remains favorable for continued rotation into economic reopening…” Building on this, Eduardo Lecubarr, chief of the Small/Mid-Cap Strategy team, sees opportunity for investors now, especially in the smaller value stocks. “We stick to our view that 2021 will be a stockpicker’s paradise with big money-making opportunities if you are willing to go against the grain… Many macro indicators did fall in January but SMid-Caps and equities in general continued to edge higher,” Lecubarr noted. And if you are prone to look at high-risk, small- to mid-cap stocks, you’ll find yourself drawn to penny stocks. The risk involved with these plays scares off the faint hearted as very real problems like weak fundamentals or overwhelming headwinds could be masked by the low share prices. So, how should investors approach a potential penny stock investment? By taking a cue from the analyst community. These experts bring in-depth knowledge of the industries they cover and substantial experience to the table. Bearing this in mind, we used TipRanks’ database to find two compelling penny stocks, according to Wall Street analysts. Both tickers boast a Strong Buy consensus rating and could climb over 200% higher in the year ahead. CNS Pharmaceuticals (CNSP) We will start with CNS Pharmaceuticals, a biotechnology company with a focus on the treatment of glioblastomas, a class of aggressive tumors that attack the braid and spinal cord. These cancers, while rare, are almost always terminal, and CNS is working a new therapy designed to more effectively cross the blood-brain barrier to attack glioblastoma. Berubicin, CNS’s flagship drug candidate, is an anthracycline, a potent class of chemotherapy drugs derived from the Streptomyces bacteria strains, and used in the treatment of a wide variety of cancers. Berubicin is the first drug in this class to show promise against glioblastoma cancers. The drug candidate has completed its Phase 1 clinical trial, in which 44% of patients showed a clinical response. This number included one patient who showed a ‘Durable Complete Response,’ defined as a demonstrated lack of detectable cancer. Following the success of the Phase 1 study, CNS applied for, and received, FDA approval of its Investigational New Drug application. This gives the company the go-ahead to conduct a Phase 2 study on adult patients, an important next step in the development of the drug. CNS plans to start the mid-stage trial in 1Q21. Based on the potential of the company’s asset in glioblastoma, and with its share price at $2.22, several analysts believe that now is the time to buy. Among the bulls is Brookline’s 5-star analyst Kumaraguru Raja who takes a bullish stance on CNSP shares. “Until now, the inability of anthracyclines to cross the blood brain barrier prevented its use for treatment of brain cancers. Berubicin is the first anthracycline to cross the blood-brain barrier in adults and access brain tumors… Berubicin has promising clinical data in a Phase 1 trial in recurrent glioblastoma (rGBM) and has Orphan drug designation for treatment of malignant gliomas from the FDA. We model approval of Berubicin for treatment of recurrent glioblastoma in 2025 based on the Phase 2 data with 55% probability of success for approval. We model peak sales of $533 million in 2032,” Raja opined. “CNS pipeline also includes WP1244 (novel DNA binding agent) that is 500x more potent than daunorubicin in inhibiting tumor cell proliferation is expected to enter the clinic in 2021… In vivo testing in orthotopic models of brain cancer showed high uptake of WP1244 by brain and subsequent antitumor activity,” the analyst added. To this end, Raja rates CNSP a Buy, and his $10 price target implies room for a stunning 350% upside potential in the next 12 months. (To watch Raja’s track record, click here) What does the rest of the Street have to say? 3 Buys and 1 Hold add up to a Strong Buy consensus rating. Given the $8.33 average price target, shares could climb ~275% in the year ahead. (See CNSP stock analysis on TipRanks) aTyr Pharma (LIFE) The next stock we’re looking at, aTyr Pharma, has a focus on inflammatory disease. Its leading drug candidate, ATYR1923, is a Neuropilin-2 (NRP2) agonist, working through the receptor proteins expressed by the NRP2 gene. These pathways are important for cardiovascular development and disease, and play a role in the inflammatory lung disease pulmonary sarcoidosis. In December, the company reported that the drug candidate had completed enrollment of 36 patients in a Phase 1b/2a clinical trial, testing the drug in the treatment of pulmonary sarcoidosis. Results of the current study are expected in 3Q21, and will inform further trials of ATYR1923, including against other forms of inflammatory lung disease. On a more immediate note, in early January the company announced top-line results of another Phase 2 clinical involving ATRY1923 – this time in the treatment of patients hospitalized with severe respiratory complications from COVID-19. The results were positive, showing that a single dose of ATYR1923 (at 3 mg/kg) resulted in a 5.5-day median recovery time. Overall, of the patients dosed in this manner, 83% saw recovery in less than one week. Covering LIFE for Roth Capital, 5-star analyst Zegbeh Jallah noted, “We like the risk profile here, with two shots on goal, and updated data details from the COVID study is expected in the coming months. Also announced recently, is that data from aTyr's Pulmonary Sarcoidosis program, will be reported in 3Q21… the success of either of these studies could result in a doubling or more of the market cap as these opportunities appear to barely be accounted for by investors.” In line with his optimistic approach, Jallah gives LIFE shares a Buy rating and his $15 price target suggests an impressive 277% potential upside for the coming year. (To watch Jallah’s track record, click here) Other analysts are on the same page. With 2 additional Buy ratings, the word on the Street is that LIFE is a Strong Buy. On top of this, the average price target is $13.33, suggesting robust growth of ~236% from the current price of $3.97. (See LIFE stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Keystone XL’s Collapse Leaves Canada’s Oil Heartland Seeking Payback

    (Bloomberg) -- The oil-rich Canadian province that was hit hard by Joe Biden’s move to kill the Keystone XL pipeline is considering seeking compensation from the U.S. through an old free-trade rule that’s still in place.Alberta, which spent C$1.5 billion ($1.2 billion) to help jump start construction of the project, may resort to a North American Free Trade Agreement provision allowing compensation claims for lost investments, Alberta Premier Jason Kenney said. While Nafta was replaced by the United States-Mexico-Canada Agreement during the Trump administration, the rule remains in place during a phase-out period.To “retroactively remove regulatory approval on the basis of which an investment was made is, in my view, a slam dunk case of a claim for damages through Nafta under the investor protection provisions,” Kenney said on a Facebook live Tuesday. “We believe we have a very strong case for damages, and we’ll be continuing to work with TC Energy on that.”The pipeline cancellation dealt another blow to an oil-dependent province that was already reeling from two crude-market crashes since 2014. TC Energy Corp.’s Keystone XL would ship more than 800,000 barrels a day of crude from Alberta’s oil sands to U.S. refineries.The project’s demise prompted TC Energy to let go of about 1,000 union workers on both sides of the border.Biden’s Keystone XL Cutoff Shocks Town Where Population DoubledAfter the U.S. president’s decision on his first day in office, Kenney said that Alberta would consider legal action and urged Canadian Prime Minister Justin Trudeau to impose trade sanctions if the Biden administration didn’t negotiate.In 2016, TC Energy sought $15 billion in compensation under Nafta after President Barack Obama rejected the project the previous year on environmental grounds, but the case was dropped after President Donald Trump approved the project early in his term.(Adds premier Kenney’s comments in third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • The S&P 500 is currently mirroring 2009-2010 to a 'creepy' degree: veteran hedge funder

    The recovery from the coronavirus crash in March 2020 looked similar to 2009 at the time. Now, almost a year later it looks even more similar, says DataTrek's Nicholas Colas.

  • Clover shares tumble after Hindenburg's attack on tech healthcare company

    Clover Health Investments (CLOV) and the special purpose acquisition company (SPAC) led by Chamath Palihapitiya that took the tech-focused healthcare company public in January came under attack on Thursday based on claims by Hindenburg Research.

  • The worst ways people will use their next stimulus check, according to Suze Orman

    The personal finance guru says plan now for the new $1,400 payment that may be coming.

  • The Ultimate Warren Buffett Stock Is In Buy Zone, But Should You Buy It?

    Berkshire Hathaway is the ultimate Warren Buffett stock. But is it a good buy? Here's what the earnings and chart show for Berkshire stock.

  • Vaxart Stock Takes a Hit, but Is It Warranted? Analyst Weighs In

    Over the past week, investors optimistically pushed Vaxart’s (VXRT) share price up by over 100%. High short-interest and anticipation of positive Phase 1 results from the study of the company’s oral Covid-19 vaccine candidate VXA-CoV-1, appears to be a particularly potent combination. However, speculation on the results of clinical trials is a risky business, and investors were left disappointed when Vaxart’s were made public on Wednesday. Since the news broke, shares crated by ~60%. So, what happened? While the vaccine was well-tolerated and caused multiple immune responses against SARS-CoV-2 antigens, it failed to produce neutralizing antibodies in the study’s participants. It is believed that a lack of neutralizing antibodies lowers the vaccine's potential to fend off COVID-19. While the market’s reaction was unequivocally negative, B. Riley analyst Mayank Mamtani looks on the bright side. “We remain intrigued with the unequivocally robust benefit noted on T cell responses, including relative to its in-class peers in the form of adenoviral vector-based C-19 vaccine candidates, particularly as it relates to the potential role in demonstrating long-lasting cross reactive immunity,” the 5-star analyst said. “In addition, we are also encouraged by safety profiles with no serious AEs noted to date and a very low event rate of solicited GI symptoms with a majority of events noted on high doses and generally reported as mild and transient.” Mamtani also says Merck’s recent discontinuation of its own oral VSV-platform based vaccine candidate was “likely safety-related.” This implies VXRT's data having “favorable readthrough to the broader platform as well as VXRT's dose optimization efforts.” Vaxart’s offering has several advantages. One being its tablet form, which could appeal to needle-shy people. It is also stable at room temperature, compared to the EUA approved vaccines’ cold storage requirements. To this end, Vaxart said it plans to advance its Covid-19 vaccine program into a Phase 2 study. All in all, Mamtani remains behind VXRT, and sticks to his Buy rating. The $16 price target remains, as well, suggesting upside of 78% from current levels. (To watch Mamtani’s track record, click here) Vaxart has only 2 other recent reviews, but both agree with Mamtani’s assessment. The 2 additional Buys add up to a Strong Buy consensus rating. The average price target is an optimistic one, and at $17.67, implies gains of 96% could be in the cards over the next 12 months. (See VXRT stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • These 4 Small-Cap EV Stocks Are Soaring. Why Now?

    There are some relatively new reasons for investors to be more bullish on most of these EV stocks. We lay them out.